<p>Greenwich LifeSciences, Inc.（纳斯达克股票代码：GLSI - 获取免费报告）副总裁 Jaye Thompson 在 8 月 12 日星期一进行了一笔交易，购入了 800 股 Greenwich LifeSciences 股票。这些股票的平均购入成本为每股 13.85 美元，总价值为 11,080.00 美元。购买完成后，副总裁现在拥有公司 263,148 股股份，价值约 3,644,599.80 美元。这笔交易已在提交给证券交易委员会的文件中披露，可以通过 SEC 网站查阅。</p>
<p>获取 <strong>Greenwich LifeSciences</strong> 警报：</p>
<p>Jaye Thompson 最近还进行了以下交易：</p>
<ul>
<li>8 月 2 日星期五，Jaye Thompson 购入了 1,000 股 Greenwich LifeSciences 股票。这些股票的平均购入成本为每股 15.15 美元，交易总额为 15,150.00 美元。</li>
<li>7 月 18 日星期四，Jaye Thompson 购入了 1,000 股 Greenwich LifeSciences 股票。这些股票的平均购入价格为每股 16.00 美元，总价值为 16,000.00 美元。</li>
</ul>
<h2>Greenwich LifeSciences 股票表现</h2>
<p>纳斯达克股票代码 GLSI 周一开盘价为 15.92 美元。Greenwich LifeSciences, Inc.一年内最低价为 7.58 美元，最高价为 21.44 美元。该股市值为 2.0505 亿美元，市盈率为-22.11，β系数为 1.61。股票的 50 天移动平均价格为 14.68 美元，200 天移动平均价格为 15.10 美元。</p>
<p>Greenwich LifeSciences（纳斯达克股票代码 GLSI - 获取免费报告）于 8 月 14 日星期三发布了其财报。公司报告本季度每股亏损（EPS）为-0.20 美元，符合分析师的一致预期。分析师预计，Greenwich LifeSciences, Inc.本财年每股盈利将达到-0.81 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>HC Wainwright 单独将 Greenwich LifeSciences 股票的目标价从 36.00 美元上调至 38.00 美元，并在 8 月 23 日星期五的研究报告中给予该公司 “买入” 评级。</p>
<p><strong>查看我们关于 GLSI 的最新研究报告</strong></p>
<h2>机构投资者对 Greenwich LifeSciences 的看法</h2>
<p>一些对冲基金和其他机构投资者最近买入和卖出了 GLSI 股票。Vanguard Group Inc.在第一季度将其在 Greenwich LifeSciences 的持股增加了 0.6%。Vanguard Group Inc.现在拥有该公司 223,102 股股份，价值 4,449,000 美元，较上一季度增持了 1,420 股。Rhumbline Advisers 在第二季度购入了一份新的 Greenwich LifeSciences 股票，价值约 117,000 美元。最后，纽约梅隆银行在第二季度买入了一份新的 Greenwich LifeSciences 股票，价值约 264,000 美元。目前有 4.16% 的股份由机构投资者和对冲基金持有。</p>
<h2>关于 Greenwich LifeSciences（获取免费报告）</h2>
<p>Greenwich LifeSciences, Inc.是一家临床阶段生物制药公司，致力于开发针对乳腺癌和其他表达 HER2/neu 的癌症的新型癌症免疫疗法。其主要产品候选药物是 GP2，一种免疫疗法，目前正在进行防止先前接受手术的患者乳腺癌复发的 III 期临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五支股票胜过 Greenwich LifeSciences</li>
<li>ESG 股票，投资者应了解的内容</li>
<li>3 支被低估的股票，现在太便宜不容忽视</li>
<li>5 个分红增长投资者的折扣机会</li>
<li>分析师视角：如何使用专家意见</li>
<li>什么是特别股息？</li>
<li>美光科技：购买 44% 价格下跌的 4 个理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0xTSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0xTSQ"/></p>
<p>_这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</p>
<p>→ 拜登的行政命令，民主党的数字货币立法，从货币金开始的第一步（从货币金开始）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTcx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTcx"/></p>
<h2>您现在是否应该投资 1,000 美元购入 Greenwich LifeSciences？</h2>
<p>在考虑购入 Greenwich LifeSciences 之前，您可能希望听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Greenwich LifeSciences 并不在名单上。</p>
<p>尽管分析师目前对 Greenwich LifeSciences 持有 “买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

GLSI

<p>格林威治生命科学公司（NASDAQ：GLSI）副总裁杰伊·汤普森于 8 月 12 日以每股 0.85 美元的价格购买了 800 股，总价为 680.00 美元。交易后，汤普森拥有 263,148 股，价值约 644,599.80 美元。此次购买是在此前以每股 0.15 美元和 0.00 美元的价格分别收购 1,000 股之后进行的。该股票开盘价为 0.92 美元，一年内的价格范围为 0.58 美元至 1.44 美元。分析师预测财年每股收益为-0.81 美元，而 HC Wainwright 将价格目标上调至 2.00 美元，并给予 “买入” 评级</p>

<p>Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) VP Jaye Thompson acquired 800 shares of Greenwich LifeSciences stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $13.85 per share, with a total value of $11,080.00. Following the completion of the purchase, the vice president now owns 263,148 shares in the company, valued at approximately $3,644,599.80. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website.</p>
<div class="lb-trans"><p>Greenwich LifeSciences, Inc.（纳斯达克股票代码：GLSI - 获取免费报告）副总裁 Jaye Thompson 在 8 月 12 日星期一进行了一笔交易，购入了 800 股 Greenwich LifeSciences 股票。这些股票的平均购入成本为每股 13.85 美元，总价值为 11,080.00 美元。购买完成后，副总裁现在拥有公司 263,148 股股份，价值约 3,644,599.80 美元。这笔交易已在提交给证券交易委员会的文件中披露，可以通过 SEC 网站查阅。</p>
</div><p>Get <strong>Greenwich LifeSciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Greenwich LifeSciences</strong> 警报：</p>
</div><p>Jaye Thompson also recently made the following trade(s):</p>
<ul>
<li>On Friday, August 2nd, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $15.15 per share, for a total transaction of $15,150.00.</li>
<li>On Thursday, July 18th, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $16.00 per share, with a total value of $16,000.00.</li>
</ul>
<div class="lb-trans"><p>Jaye Thompson 最近还进行了以下交易：</p>
<ul>
<li>8 月 2 日星期五，Jaye Thompson 购入了 1,000 股 Greenwich LifeSciences 股票。这些股票的平均购入成本为每股 15.15 美元，交易总额为 15,150.00 美元。</li>
<li>7 月 18 日星期四，Jaye Thompson 购入了 1,000 股 Greenwich LifeSciences 股票。这些股票的平均购入价格为每股 16.00 美元，总价值为 16,000.00 美元。</li>
</ul>
</div><h2>Greenwich LifeSciences Stock Performance</h2>
<div class="lb-trans"><h2>Greenwich LifeSciences 股票表现</h2>
</div><p>NASDAQ:GLSI opened at $15.92 on Monday. Greenwich LifeSciences, Inc. has a one year low of $7.58 and a one year high of $21.44. The stock has a market cap of $205.05 million, a PE ratio of -22.11 and a beta of 1.61. The stock has a 50 day moving average price of $14.68 and a 200 day moving average price of $15.10.</p>
<div class="lb-trans"><p>纳斯达克股票代码 GLSI 周一开盘价为 15.92 美元。Greenwich LifeSciences, Inc.一年内最低价为 7.58 美元，最高价为 21.44 美元。该股市值为 2.0505 亿美元，市盈率为-22.11，β系数为 1.61。股票的 50 天移动平均价格为 14.68 美元，200 天移动平均价格为 15.10 美元。</p>
</div><p>Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.20). As a group, analysts predict that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Greenwich LifeSciences（纳斯达克股票代码 GLSI - 获取免费报告）于 8 月 14 日星期三发布了其财报。公司报告本季度每股亏损（EPS）为-0.20 美元，符合分析师的一致预期。分析师预计，Greenwich LifeSciences, Inc.本财年每股盈利将达到-0.81 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, HC Wainwright upped their price objective on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 23rd.</p>
<div class="lb-trans"><p>HC Wainwright 单独将 Greenwich LifeSciences 股票的目标价从 36.00 美元上调至 38.00 美元，并在 8 月 23 日星期五的研究报告中给予该公司 “买入” 评级。</p>
</div><p><strong>View Our Latest Research Report on GLSI</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 GLSI 的最新研究报告</strong></p>
</div><h2>Institutional Investors Weigh In On Greenwich LifeSciences</h2>
<div class="lb-trans"><h2>机构投资者对 Greenwich LifeSciences 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of GLSI. Vanguard Group Inc. boosted its holdings in Greenwich LifeSciences by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company's stock valued at $4,449,000 after purchasing an additional 1,420 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Greenwich LifeSciences during the 2nd quarter valued at approximately $117,000. Finally, Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences in the second quarter valued at approximately $264,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买入和卖出了 GLSI 股票。Vanguard Group Inc.在第一季度将其在 Greenwich LifeSciences 的持股增加了 0.6%。Vanguard Group Inc.现在拥有该公司 223,102 股股份，价值 4,449,000 美元，较上一季度增持了 1,420 股。Rhumbline Advisers 在第二季度购入了一份新的 Greenwich LifeSciences 股票，价值约 117,000 美元。最后，纽约梅隆银行在第二季度买入了一份新的 Greenwich LifeSciences 股票，价值约 264,000 美元。目前有 4.16% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>About Greenwich LifeSciences (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Greenwich LifeSciences（获取免费报告）</h2>
</div><p>Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.</p>
<div class="lb-trans"><p>Greenwich LifeSciences, Inc.是一家临床阶段生物制药公司，致力于开发针对乳腺癌和其他表达 HER2/neu 的癌症的新型癌症免疫疗法。其主要产品候选药物是 GP2，一种免疫疗法，目前正在进行防止先前接受手术的患者乳腺癌复发的 III 期临床试验。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Greenwich LifeSciences</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>3 Undervalued Stocks That Are Too Cheap to Ignore Right Now</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>The Analyst Edge: How to Use Expert Opinions</li>
<li>What is a Special Dividend?</li>
<li>Micron Technology: 4 Reasons to Buy the 44% Price Dip</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五支股票胜过 Greenwich LifeSciences</li>
<li>ESG 股票，投资者应了解的内容</li>
<li>3 支被低估的股票，现在太便宜不容忽视</li>
<li>5 个分红增长投资者的折扣机会</li>
<li>分析师视角：如何使用专家意见</li>
<li>什么是特别股息？</li>
<li>美光科技：购买 44% 价格下跌的 4 个理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0xTSQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=GLSI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p>_这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</p>
</div><p>→ Biden's Executive Order, Dems Digital Money Legislation, First Step To (From Monetary Gold)(Ad)</p>
<div class="lb-trans"><p>→ 拜登的行政命令，民主党的数字货币立法，从货币金开始的第一步（从货币金开始）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTcx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9571&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Greenwich LifeSciences right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购入 Greenwich LifeSciences？</h2>
</div><p>Before you consider Greenwich LifeSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购入 Greenwich LifeSciences 之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Greenwich LifeSciences 并不在名单上。</p>
</div><p>While Greenwich LifeSciences currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管分析师目前对 Greenwich LifeSciences 持有 “买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) 副总裁 Jaye Thompson 购买了 800 股公司股票